151 related articles for article (PubMed ID: 23840879)
1. Examination of MARCO activity on dendritic cell phenotype and function using a gene knockout mouse.
Komine H; Kuhn L; Matsushita N; Mulé JJ; Pilon-Thomas S
PLoS One; 2013; 8(7):e67795. PubMed ID: 23840879
[TBL] [Abstract][Full Text] [Related]
2. Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.
Matsushita N; Komine H; Grolleau-Julius A; Pilon-Thomas S; Mulé JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):875-84. PubMed ID: 20054688
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
4. Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays.
Grolleau A; Misek DE; Kuick R; Hanash S; Mulé JJ
J Immunol; 2003 Sep; 171(6):2879-88. PubMed ID: 12960310
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
6. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
Marchi LH; Paschoalin T; Travassos LR; Rodrigues EG
Cancer Gene Ther; 2011 Feb; 18(2):110-22. PubMed ID: 20885448
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
Kikuchi T; Moore MA; Crystal RG
Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo.
Li YL; Wu YG; Wang YQ; Li Z; Wang RC; Wang L; Zhang YY
World J Gastroenterol; 2008 Dec; 14(46):7127-32. PubMed ID: 19084922
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
[TBL] [Abstract][Full Text] [Related]
12. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
[TBL] [Abstract][Full Text] [Related]
13. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
14. Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses.
Harjunpää H; Somermäki R; Saldo Rubio G; Fusciello M; Feola S; Faisal I; Nieminen AI; Wang L; Llort Asens M; Zhao H; Eriksson O; Cerullo V; Fagerholm SC
Oncoimmunology; 2024; 13(1):2369373. PubMed ID: 38915784
[TBL] [Abstract][Full Text] [Related]
15. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
17. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
18. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.
Weigel BJ; Nath N; Taylor PA; Panoskaltsis-Mortari A; Chen W; Krieg AM; Brasel K; Blazar BR
Blood; 2002 Dec; 100(12):4169-76. PubMed ID: 12393694
[TBL] [Abstract][Full Text] [Related]
20. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
